Early lessons from the NewCo Model

A wide-ranging discussion on biotech’s outlook in the capital markets converged on the sector’s hottest topic, the NewCo Model, and its influence on the strategy and behavior of U.S. and European biotechs. 

The conversation was part of a Capital Markets Preview webinar co-hosted by BioCentury and Oppenheimer & Co. The panelists included Oppenheimer’s Michael Margolis, EQT Life Sciences’ Christoph Broja, General Atlantic’s Brett Zbar, MPM Capital’s Chris Bardon, and Ji Li, former head of business development at Beigene Ltd. (NASDAQ:ONC; HKEX:6160; Shanghai:688235)...